Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease (vol 13,Pg 655-675,2024)

被引：0

作者：

Frank, Samuel ^{[1
]}

Anderson, Karen E. ^{[2
]}

Fernandez, Hubert H. ^{[3
]}

Hauser, Robert A. ^{[4
]}

Claassen, Daniel O. ^{[5
]}

Stamler, David ^{[6
]}

Factor, Stewart A. ^{[7
]}

Jimenez-Shahed, Joohi ^{[8
]}

Barkay, Hadas ^{[9
]}

Wilhelm, Amanda ^{[10
]}

Alexander, Jessica K. ^{[10
]}

Chaijale, Nayla ^{[10
]}

Barash, Steve ^{[10
]}

Savola, Juha-Matti ^{[11
]}

Gordon, Mark Forrest ^{[10
]}

Chen, Maria ^{[10
]}

机构：

[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Kirstein 228, Boston, MA 02215 USA

[2] Georgetown Univ, Washington, DC USA

[3] Cleveland Clin, Cleveland Hts, OH USA

[4] Univ S Florida, Parkinsons Dis & Movement Disorders Ctr, Tampa, FL USA

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Teva Branded Pharmaceut Prod R&D Inc, La Jolla, CA USA

[7] Emory Univ, Atlanta, GA USA

[8] Icahn Sch Med Mt Sinai, New York, NY USA

[9] Teva Pharmaceut Ind Ltd, Netanya, Israel

[10] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA

[11] Teva Pharmaceut Int GmbH, Basel, Switzerland

来源：

NEUROLOGY AND THERAPY | 2024年 / 13卷 / 06期

关键词：

D O I：

10.1007/s40120-024-00660-3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：1747 / 1749

页数：3

共 25 条

[21] Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial (vol 22, pg 494, 2023)
Granit, V
Benatar, M.
Kurtoglu, M.
[J]. LANCET NEUROLOGY, 2023, 22 (09) : E10 - E10
[22] PARKINSONISM AND RELATED DISORDERS 122 (2024) 106854 SOMNOLENCE-RELATED EVENTS OVER TIME DURING VALBENAZINE TREATMENT FOR CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
Stimming, E. Furr
Claassen, D. O.
Kayson, E.
Goldstein, J.
Mehanna, R.
Hinton, S. C.
Klepitskaya, O.
Zhang, H.
Karpuram, S.
Thai-Cuarto, D.
Liang, G.
Haubenberger, D.
[J]. PARKINSONISM & RELATED DISORDERS, 2024, 122
[23] Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial
Stimming, Erin Furr
Claassen, Daniel
Kayson, Elise
Goldstein, Jody
Mehanna, Raja
Zhang, Hui
Liang, Grace S.
Haubenberger, Dietrich
[J]. LANCET NEUROLOGY, 2023, 22 (06) : 494 - 504
[24] A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids (vol 13, pg 29, 2002)
Vaddad, KS
Soosai, E
Chiu, E
Dingjan, P
[J]. NEUROREPORT, 2002, 13 (02) : COVER3 - COVER3
[25] Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review (vol 13, pg 1571, 2024)
Blumenfeld, Andrew M.
Mechtler, Laszlo
Cook, Lisa
Rhyne, Christopher
Jenkins, Brian
Hughes, Olivia
Dabruzzo, Brett
Manack Adams, Aubrey
Diamond, Merle
[J]. PAIN AND THERAPY, 2025, 14 (01) : 441 - 444

← 1 2 3 →